Amgen Inc
USUSDAmgen Inc (HK:4332) — Biotechnology: Biological Products (No Diagnostic Substances). Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 4. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- amgen.com
- Investor Relations
- investors.amgen.com/
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Hauptsitz
- Thousand Oaks, United States
- CEO
- Robert A. Bradway
- Mitarbeiter
- 17 900
- Gegründet
- 1980
- Delistet
- 10.10.2026 (HK:4332)
- Ausstehende Aktien
- 540.63 Mio. Stand 2026-07-30
- Streubesitz
- 539.16 Mio.
- Marktkapitalisierung
- 226.05 Mrd. USD
- Insider
- 0.23%
- Institutionelle Anleger
- 85.02%
- Branche (SIC)
- Biological Products, (No Diagnostic Substances)
- Rechtsform
- XTIQ
- ISIN
- US0311621009
- LEI
- 62QBXGPJ34PQ72Z12S66
- Ausschüttungsquote
- 60.4%
- FCF
- 10.2 Mrd. USD
- Payout / FCF
- 52%
- Schulden
- 57.3 Mrd. USD4.3 J. FCF
- Dividendenserie
- 15 J.
- Gewinn, FCF und gezahlte Dividenden — für die 12 Monate bis 30.06.2026 (letzter Bericht des Unternehmens).
Beschreibung
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Börsen und Ticker
| Börse | Ticker | Währung | Preis | Typ |
|---|---|---|---|---|
| US USA Stocks | AMGN primär | USD | 417.57 +0.65% | Stammaktie |
| HK Hong Kong Stock Exchange | 4332 zusätzlich | HKD | — | |
| LSE London Stock Exchange | 0R0T IOB | USD | 411.854 +1.17% | Stammaktie |
| MX Mexican Stock Exchange | AMGN zusätzlich | MXN | 7 500.0098 +0.00% | Stammaktie |
| XETRA Xetra | AMG zusätzlich | EUR | 367.95 -1.39% | Stammaktie |
Dividenden
Amgen Inc (AMGN) zahlt vierteljährlich Dividenden. Pro Jahr (12 Monate bis einschließlich der zuletzt angekündigten Zahlung): 9.94 USD pro Aktie (Zahlungen: 4). Das entspricht etwa 2.38% des aktuellen Aktienkurses. Basierend auf der Zahlungshistorie wird der nächste Ex-Dividenden-Tag um den 20.11.2026 erwartet. Ununterbrochene Dividendengeschichte: 15 Jahre.
| Ex-tag | Auszahlung | Betrag | % | Typ | Ticker |
|---|---|---|---|---|---|
| 2026-08-21 | 2026-09-11 | 2.5200 USD | 0.6/2.3 % | vierteljährlich | US:AMGN |
| 2026-05-15 | 2026-06-05 | 2.5200 USD | 0.7/2.9 % | vierteljährlich | US:AMGN |
| 2026-02-13 | 2026-03-06 | 2.5200 USD | 0.7/2.6 % | vierteljährlich | US:AMGN |
| 2025-11-21 | 2025-12-12 | 2.3800 USD | 0.7/2.8 % | vierteljährlich | US:AMGN |
| 2025-08-22 | 2025-09-12 | 2.3800 USD | 0.8/3.2 % | vierteljährlich | US:AMGN |
| 2025-05-16 | 2025-06-06 | 2.3800 USD | 0.9/3.4 % | vierteljährlich | US:AMGN |
| 2025-02-14 | 2025-03-07 | 2.3800 USD | 0.8/3.1 % | vierteljährlich | US:AMGN |
| 2024-11-18 | 2024-12-09 | 2.2500 USD | 0.8/≈3.2 % | vierteljährlich | US:AMGN |
| 2024-08-16 | 2024-09-06 | 2.2500 USD | 0.5/≈2.2 % | vierteljährlich | US:AMGN |
| 2024-05-16 | 2024-06-07 | 2.2500 USD | 0.5/≈2.2 % | vierteljährlich | US:AMGN |
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| Blackrock Inc. | 9.13% | 49.36 Mio. | 2026-06-30 |
| Vanguard Capital Managem… | 6.52% | 35.25 Mio. | 2026-06-30 |
| State Street Corporation | 5.65% | 30.56 Mio. | 2026-06-30 |
| Capital World Investors | 5.38% | 29.08 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 17.13 Mio. | 2026-06-30 |
| Invesco Ltd. | 3.02% | 16.32 Mio. | 2026-06-30 |
| Geode Capital Management… | 2.9% | 15.7 Mio. | 2026-06-30 |
| Charles Schwab Investmen… | 2.78% | 15.03 Mio. | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.75% | 14.85 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 13.99 Mio. | 2026-06-30 |
| Morgan Stanley | 2.53% | 13.65 Mio. | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.15% | 11.61 Mio. | 2026-08-31 |
| SCHWAB STRATEGIC TRUST-S… | 1.81% | 9.79 Mio. | 2026-05-31 |
| Income Fund of America | 1.44% | 7.76 Mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 7.28 Mio. | 2026-07-31 |
| Wells Fargo & Company | 1.34% | 7.24 Mio. | 2026-06-30 |
| AMERICAN BALANCED FUND | 1.31% | 7.09 Mio. | 2026-06-30 |
| Fidelity Concord Street… | 1.29% | 6.98 Mio. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 6.6 Mio. | 2026-08-31 |
| WASHINGTON MUTUAL INVEST… | 1.16% | 6.27 Mio. | 2026-06-30 |
| BRADWAY ROBERT A (Chief… | ≈0.12% | 657 299 | 2026-05-05 |
| SANTOS ESTEBAN (Officer) | ≈0.02% | 84 279 | 2026-05-05 |
| GORDON MURDO (Officer) | ≈0.01% | 51 837 | 2026-05-05 |
| GRIFFITH PETER H. (Chief… | ≈0.01% | 50 706 | 2026-05-05 |
| REESE DAVID M. (Chief Te… | ≈0.01% | 42 812 | 2026-05-05 |
| GRAHAM JONATHAN P (Gener… | ≈0.01% | 40 211 | 2026-05-05 |
| BRADNER JAMES E. (Office… | ≈0.01% | 30 462 | 2026-05-05 |
| ECKERT ROBERT ANDREW (Di… | ≈0% | 26 251 | 2026-05-19 |
| JACKS TYLER (Director) | ≈0% | 18 284 | 2026-05-19 |
| KULLMAN ELLEN JAMISON (D… | ≈0% | 14 536 | 2026-05-19 |
